ArticleBMC oral health2025
Melatonin may be an alternative to amifostine in salivary gland protection in irradiated rats.
Article in BMC oral health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe aim of this study was to compare the effects of systemic amifostine (Ami) and melatonin (Mel) alone and the combined use of the drugs on apoptotic, oxidative, biochemical and morphometric outcomes caused by radiotherapy (RT)-induced salivary gland injury.
methods40 female Sprague-Dawley rats were divided into 5 groups: Control, RT, RT + Ami, RT + Mel, RT + Ami + Mel. 30 min before single dose 5 Gy RT, Ami (200 mg/kg) was administered for 3 days and Mel (10 mg/kg) was administered for 15 days. Caspase-3 and Ki-67 apoptotic activity markers and NF-Κb/p65, a transcription factor, were analyzed immunohistochemically, and serum inflammatory cytokine (IL-1β, IL-10, IL-6, TNF-α) and oxidative stress (8-OHdG and OSI) levels were analyzed biochemically.
resultsThe destructive effect of RT on the salivary gland has been clearly demonstrated at the level of histopathological damage, apoptotic activity, oxidative stress and biochemical parameters. When the two drug groups were compared, no statistical difference was found (p > 0.05); Mel prophylaxis provided significant decreases, especially in IL-1β and OSI levels (p < 0.05). With the combined use of both drugs, a slightly synergistic effect at the inflammatory, oxidative and apoptotic levels has been proven.
conclusionMel has a salivary radioprotective activity comparable to Ami. The combined use of drugs has not provided a significant therapeutic advantage in preventing salivary inflammatory stress and apoptotic changes. Thus, Mel may be an alternative to Ami to prevent RT-induced salivary gland damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.